Sage Journals: Discover world-class research

Abstract

The pancreas has physiologically important endocrine and exocrine functions; secreting enzymes into the small intestine to aid digestion and releasing multiple peptide hormones via the islets of Langerhans to regulate glucose metabolism, respectively. Insulin and glucagon, in combination with ghrelin, pancreatic polypeptide and somatostatin, are the main classical islet peptides critical for the maintenance of blood glucose. However, pancreatic islets also synthesis numerous ‘nonclassical’ peptides that have recently been demonstrated to exert fundamental effects on overall islet function and metabolism. As such, insights into the physiological relevance of these nonclassical peptides have shown impact on glucose metabolism, insulin action, cell survival, weight loss, and energy expenditure. This review will focus on the role of individual nonclassical islet peptides to stimulate pancreatic islet secretions as well as regulate metabolism. In addition, the more recognised actions of these peptides on satiety and energy regulation will also be considered. Furthermore, recent advances in the field of peptide therapeutics and obesity-diabetes have focused on the benefits of simultaneously targeting several hormone receptor signalling cascades. The potential for nonclassical islet hormones within such combinational approaches will also be discussed.

Keywords

β-cell insulin secretion nonclassical islet peptides dual agonist triagonist

Introduction

Metabolic abnormality can occur due to a range of genetic or acquired disorders including diabetes and obesity.¹ These disorders involve a disturbance of metabolomics involved in energy balance regulation.² Unfortunately, the prevalence of obesity and related type 2 diabetes mellitus (T2DM) is consistently increasing.³ The underlying pathophysiological feature of T2DM, and other related forms of diabetes, is primarily associated with a loss in function and/or mass of insulin secreting beta-cells (β-cells) of the endocrine pancreas.⁴ The pancreas is situated behind the peritoneum and consists of a head, body, and tail that is close to the duodenum. Most pancreatic mass (90%) is made of exocrine cells grouped in lobules and separated by connective tissue.⁵ The product of exocrine cells, an alkaline liquid concentrated with digestive enzymes, is drained via a pancreatic duct and enters the small intestine to aid digestion.⁶ However, throughout the exocrine tissue clusters of endocrine cells called ‘islets of Langerhans’ exist, these islets are known to play a vital role in controlling metabolism, and especially blood glucose equilibrium (Figure 1).⁷ The main hormones secreted from pancreatic islet cells are glucagon from alpha (α) cells, insulin from β-cells, somatostatin from delta (Δ) cells and pancreatic polypeptide (PP), with release believed to be under strict endocrine, paracrine, and neuronal control.⁸ However, several nonclassical islet peptides have also been described and shown to possess similarly important effects on islet function (Table 1). This is epitomised by recent acceptance of ghrelin as an islet-derived peptide secreted from epsilon (ε) cells with established intra-islet actions,⁹ as well as effects on metabolism beyond the pancreas.¹⁰ As such, although much research on pancreatic islets and T2DM treatments has focused on the classic peptide hormones,¹¹ the role and therapeutic applicability of nonclassic islets peptide hormones also needs to be considered.

Figure 1.

Endocrine pancreatic cell types and their peptide secretions. Exocrine pancreatic acinar cells constitute most of the pancreatic tissue, these cells produce digestive enzymes which are transported via the pancreatic ducts. The endocrine pancreas is illustrated with all cell types; alpha, beta, delta, PP, and epsilon. The cells are arranged in compact islets and secrete a number of classical and ‘nonclassical’ peptides, as depicted. PP indicates pancreatic polypeptide.

Table 1.

Classical and ‘nonclassical’ peptides secreted by the pancreas. Table includes the peptides main origin tissue (including gut and CNS) and cells of origin. The key secretory initiators are stated and the effect each peptide has on the pancreatic islet.

Peptide	Origin		Regulation of secretion	Effects on Islet
Classical	Tissue	Cell
Insulin	Pancreas	β-cell	Plasma glucose, FFA, glucagon	Inhibits glucagon
Glucagon	Pancreas	α-cell	Amino acids released by digestion	Stimulates insulin secretion
Somatostatin	Pancreas	Δ-cell	Glucagon	Inhibits release of insulin and glucagon
Pancreatic polypeptide	Pancreas	PP-cell	To be determined	Inhibits insulin
Ghrelin	Pancreas	epsilon cell	Dietary intake of nutrients	Inhibits insulin
Nonclassical
GLP-1	Pancreas/Gut	α-cell/Intestinal L-cell	Ingested glucose load	Increases insulin secretion, β-cell mass, inhibits glucagon, apoptosis
GLP-2	Pancreas/Gut	α-cell/L-cell	Dietary intake of nutrients	Positive effects on β-cell proliferation and apoptosis
GIP	Pancreas/Gut	α-cell/Intestinal K-cell	Ingested glucose load	Causes insulin secretion, and β-cell proliferation
PYY	Pancreas/Gut	α-cell/Intestinal L-cell	Dietary intake of nutrients	β-cell proliferative and anti-apoptotic effects
Gastrin	Pancreas/Gut	β-cell/G-cell	Stomach distension, digested proteins	Causes insulin secretion
CCK	Pancreas/Gut	β-cell/EEC cell	Stomach distension, digested proteins	β-cell proliferative and anti-apoptotic effects
Xenin-25	Pancreas/Gut	Islets/K-cell	Dietary intake of nutrients	Increases GIP-mediated insulin secretion
Secretin	Pancreas/Gut	β-cell/S-cells	Dietary intake of nutrients/Stomach acid	Inhibits glucagon
Urocortin3	Pancreas	α-cell/β-cell	Plasma glucose (co-secreted with insulin)	Promotes insulin secretion
Amylin	Pancreas	β-cell	Dietary intake of nutrients	Inhibits insulin secretion and β-cell proliferation
Vasopressin	Pancreas/CNS	β-cell/M-cell	Response to hypertonicity	Promotes Insulin secretion, β-cell proliferative and anti-apoptotic effects
Oxytocin	Pancreas/CNS	β-cell/M-cell	Related to reproductive function	Promotes insulin secretion, β-cell proliferative and anti-apoptotic effects

Abbreviations: CCK, cholecystokinin; CNS, central nervous system; EEC, enteroendocrine cells; FFA, free fatty acid; GIP, glucose dependent insulinotropic peptide; GLP, glucagon-like peptide; PYY, Peptide Tyrosine Tyrosine.

Classical Islet Peptides

As noted above, the endocrine pancreas secretes 5 peptide hormones, namely, glucagon, insulin, somatostatin, PP, and ghrelin, from specific cell types, that play a critical role in glucose homeostasis and energy metabolism⁸ (Table 1). A secretory interplay between glucagon and insulin balances blood glucose in healthy individuals.¹² Glucagon is released in times of low glucose to promote hepatic glycogenolysis,¹³ whereas insulin is released in response to raised glucose to promote glycogenesis and lipogenesis.¹⁴ The underlying molecular processes of insulin exocytosis in response to glucose is well known and involves the closure of K_ATP channels, β-cell membrane depolarisation, calcium influx, and subsequent secretion of insulin.¹⁵ During the onset of diabetes this relationship is negatively affected and insulin secretion rates decrease,¹⁶ this is often combined with desensitisation of the insulin receptor (IR) located on peripheral tissues.¹⁷ As such, treatment of diabetes has focused predominantly on addressing the deficit in insulin secretion through administration of direct insulin secretagogues or insulin replacement therapy,¹⁸ as well as therapies aimed at resensitising the IR. In this regard, there are a variety of nonclassical islet peptides that can trigger or potentiate insulin secretion, improve β-cell survival or increase insulin sensitivity through modulation of G-protein coupled receptors (GPCRs)⁸ (Figure 1).

Nonclassical Islet Peptides – Pancreatic Effects

Incretin and related peptides

As well as the classical islet peptides, there are a number of other peptide hormones known to be synthesised and released within pancreatic islets, often termed ‘nonclassical’ islet peptides⁸ (Figure 1). The incretin hormones, namely glucagon-like peptide (GLP)-1 and glucose dependent insulinotropic peptide (GIP), are the most comprehensively studied nonclassical islet peptides.¹⁹ Typically, GLP-1 and GIP are considered to be endocrine L- and K-cell derived peptides released in response to nutrient ingestion.²⁰ Elegant studies have described the secretory dynamics of these 2 hormones from the gut.²¹ However, both GIP and GLP-1 have also been shown to be synthesised and released locally within pancreatic islets, with important paracrine effects.²² Glucagon-like peptide-1 has direct and indirect actions on α-cells, directly inhibiting glucagon²³ and indirectly increasing intra-islet regulation via somatostatin,²⁴ GIP effects on glucagon are glucose dependent. As such, at low levels of glycaemia, glucagon release is increased by GIP with minimal effect on insulin, with this glucagonotropic effect disappearing at higher glucose levels.²⁵ Mechanistically, GLP-1 and GIP potentiate insulin secretion by binding to specific GPCRs located on pancreatic β-cells to increase cAMP²⁶ and activate Epac and protein kinase A (PKA).²⁰ The process of GIP and GLP-1 induced insulin secretion is well described, primarily due to increased interest in the ‘incretin effect’ over the past decades, clearly defining how the intestinally released hormones potentiate insulin release following meals.²⁷ These mechanisms supplement glucose-mediated effects, closing K⁺_ATP and Kv channels and promoting depolarisation of the β-cell. Calcium channels are also sensitised via PKA and Epac.²⁰ Together this facilitates intracellular calcium stores to be released, resulting in insulin secretion. Glucagon-like peptide-2 (GLP-2) is another proglucagon derived peptide, its principle role is to maintain intestinal mucosal villus epithelium and aid gut absorption.²⁸ In addition, GLP-2 acts as an intestinal growth factor, with clinical application for short bowel syndrome.²⁹ Glucagon-like peptide-2 receptors are expressed on rodent α-cells ³⁰ and linked to increased glucagon secretion.³¹ Notably, GLP-2 also has been demonstrated to possess proliferative and anti-apoptotic effects in β-cells,³² highlighting a role in glucose homeostasis. However, GLP-2 has no effect on insulin secretion from β-cells, or isolated mouse islets.³¹

Peptide Tyrosine Tyrosine

Peptide Tyrosine Tyrosine (PYY) is a 36 amino acid peptide hormone best known as being released postprandially from enteroendocrine L-cells, similar to GLP-1.³³ Moreover, both hormones are expressed within pancreatic islets and released locally (Figure 1).³⁴ Peptide Tyrosine Tyrosine and neuropeptide Y (NPY) both activate neuropeptide Y receptors (NPYRs) and represent promising antidiabetes targets.³⁴ Although the peptides activate the same family of receptors, their effects on islet secretions differ due to differences in receptor affinity and specificity. Early rodent studies indicated plasma insulin levels were reduced or unaffected by PYY.³⁵ Further studies in isolated islets and human β-cells also revealed minimal effect of PYY on insulin secretion, although β-cell anti-apoptotic and proliferative effects were noted.³⁶ As such, transgenic mouse models overexpressing PYY exhibited enhanced glucose facilitated insulin responses and amplified islet number.³⁷ Consistent with these findings, knock out of PYY in the gut and pancreas causes disruption of islet morphology and decreased β-cell mass.³⁸ In addition, streptozotocin-induced insulin deficiency and β-cell destruction is linked to reduced islet PYY levels, whereas hydrocortisone-induced increases of β-cell mass are linked to elevated PYY levels.³⁶ Furthermore, in the developing foetal pancreas PYY is detectable at a very early stage,³⁹ indicating potential effects on pancreatic islet development. For PYY effects, it is also important to note the distinct receptor specificity of the 2 main circulating molecules and pancreatic expression of these receptors. As such, PYY (1-36) binds and activates all NPYRs,⁴⁰ whereas PYY (3-36) is an NPYR2-specific molecule. PYY can prevent glucagon release from isolated islets, although NPY receptors are thought to be specifically on β-cells.⁴¹ This would suggest PYY modulation of glucagon occurs via indirect pathways and could involve insulin or somatostatin release.⁴² The ability of PYY to restore deranged insulin and glucagon secretions in T2DM, is of clinical significance and these findings justify further investigation.⁴³ Similar to PYY, the neurotransmitter NPY has also been linked to decreased insulin and glucagon release.^44,45

Gastrin and cholecystokinin

Receptors for gastrin and cholecystokinin (CCK), namely CCK1 receptors, are highly expressed on α- and β-cells and both are synthesised and secreted by islets and effect islet function.⁴⁶ Hypergastrinaemia is linked to excessive insulin production and low blood glucose,⁴⁷ and both hormones induce secretion with or without glucose.⁴⁸ There is conflicting evidence on the effect of gastrin on glucagon secretion, with some models highlighting a stimulatory effect ⁴⁹ whereas others conflict these findings.⁵⁰ Disruption of the gastrin gene in mice does not affect islet morphology or basal glucagon levels, but does cause substandard glucagon secretion in response to insulin caused hypoglycaemia.⁵¹ Gastrin in combination with epidermal growth factor has been found to cause β-cell regeneration in mice after near total destruction by alloxan.⁵² In respect to CCK, little effect on glucagon release has been recorded,⁵³ but a close relationship to GLP-1 has been identified.⁵⁴ Research has focused on an intra-islet loop based on local islet secretion of these peptides, whether GLP-1 and CCK originating from the gut have the same islet effects is unknown. Sulphation of CCK at a tyrosine located 7 residues from the C-terminus is crucial for CCK bioactivity,⁵⁵ this post-translational modification allows for strengthened protein-protein interaction.⁵⁶ Glucagon-like peptide-1 secreted from the α-cell targets the β-cell to stimulate CCK production, while CCK can also stimulate α-cells to release GLP-1 increasing β-cell survival and proliferation, in a positive feedback loop within β-cells.^54,57 Mechanistically, CCK1 receptor stimulation phosphorylates PKA and phospholipase C (PLC) increasing intracellular calcium concentrations via the L-channel, this causes positive bias on PLC activity. Increased calcium and diacylglycerol produced by PLC activates protein kinase C⁵⁸ which ultimately opens gated calcium channels.⁵⁹ Further work is required to fully assess the therapeutic promise of both gastrin and CCK, especially in relation to potential off-target side effects.⁴⁷

Urocortin3 and islet amyloid polypeptide

Urocortin3 (Ucn3) is a peptide hormone expressed by mature β-cells, early work revealed insulin and glucagon release to increase in response to Ucn3 treatment.⁶⁰ Interestingly, Ucn3 may also have benefits on plasma glucose⁶¹ and glucose tolerance.⁶⁰ This has driven new studies to define the physiological role of Ucn3, and it is known that Ucn3 amplifies somatostatin release to modulate insulin and glucagon secretion.⁶² Somatostatin receptors (SSTRs) have been acknowledged on α- and β-cells.⁶³ Rodent studies reveal inhibition of glucagon and insulin is facilitated through SSTRs 5 and 2, respectively; knockout of these receptors results in variation of basal and glucose stimulated insulin section.⁶⁴ In T2DM, Ucn3 expression is reduced in β-cells and causes an unstable glycaemic state.⁶⁵ Islet amyloid polypeptide (IAPP, amylin) is a peptide co-secreted from β-cells with insulin in response to glucose and fatty acids at a ratio of 15:1 (insulin:amylin).⁶⁶ Currently, 3 amylin receptors have been identified, namely AMY₁, AMY₂, and AMY₃⁶⁷ and activation by amylin is thought to regulate insulin secretion under certain disease states or conditions.⁶⁸ Knockout studies in β-cells have revealed reduced amylin causes increased glucose-induced insulin secretion, whereas treatment of amylin at physiological levels inhibits insulin secretion.⁶⁹ Amylin also controls β-cell proliferation in a glucose dependent manner. As such, at high glucose concentrations amylin inhibits proliferation and at low levels promotes β-cell proliferation.⁷⁰

Xenin-25 and neurotensin

Xenin-25 is a peptide hormone traditionally characterised as being secreted from endocrine K-cells with GIP,⁷¹ but xenin-25, as well as the related neurotensin hormone, have also been found in pancreatic islets, alongside neurotensin receptors (NTSRs).⁷² The main pancreatic effects of xenin include increasing PP secretion and amplifying the effects of GIP,⁷³ indirectly effecting insulin and glucagon release. Xenin-25 interacts with acetylcholine signalling pathways to increase β-cell insulin secretion, and this is thought to be independent of NTSRs.⁷⁴ This may explain slight differences in the pancreatic effect of xenin-25 and neurotensin, despite both being NTSR ligands. Proliferation in rodent and human β-cells is enhanced by xenin-25 and neurotensin, suggesting the peptides as promising antidiabetic agents.⁴⁴ The signalling mechanisms involved in insulin and glucagon secretion for xenin-25, differ between human and mouse models in response to co-treatment with GIP.⁷⁴ In mice, positive effects of co-treatment were seen under hyperglycaemic conditions. In humans, effects on insulin and glucagon where specifically recorded in patients with reduced glucose tolerance, but not in patients with T2DM.⁷⁴ Cholinergic signalling may act as a regulatory mechanism to increase insulin secretion, and failure is thought to lead to the development of T2DM.⁷⁵ In mice, atropine treatment inhibited the effect of xenin on GIP-mediated insulin and glucagon secretion implicating cholinergic signalling⁷³ whereas in humans there is no inhibition.⁷⁴

Vasopressin, oxytocin, and secretin

Vasopressin (AVP) and oxytocin (OT) are neuropeptides and components of a cohesive system,⁷⁶ with synthesis also evidenced within the pancreas.^77,78 Oxytocin receptor knockout (OTKO) mice have increased sensitivity to AVP⁷⁹ and AVP causes a significant concentration dependent increase of insulin secretion in rodent (BRIN BD11) and human (1.1B4) β-cells,⁷⁷ but has no effect on glucagon secretion. AVP receptors; V1a, V1b, V2 are highly abundant on β-cells and antagonism of V1a, V1b has a negative effect on AVP-mediated insulin secretion.⁷⁷ AVP also has positive effects on β-cell proliferation and survival.⁷⁷ Oxytocin (OT) is known to stimulate insulin and glucagon secretion and have positive effects on insulin action, glucose intolerance and islet hypertrophy.⁷⁸ Calcium-calmodulin kinase (Ca-CAMKK), phosphoinositide-3-kinase (PI3K) and AMP-activated protein kinase (AMPK) pathways may mediate these effects⁸⁰ and serotonin (5-HT) and dopamine may have supplementary properties.⁷⁶ Secretin is produced in the duodenum by S-cells and in the pancreas by secretin producing islets,⁸¹ it consists of 27 amino acids with a sequence similar to glucagon and GIP.⁸² Following an oral glucose load, secretin maintains blood glucose control through initiating insulin release,⁸³ while other work has detailed suppressive effects on α-cell function and glucagon release.⁸⁴ Interestingly, secretin has also been found to enhance the effects of CCK to increase β-cell proliferation and mass.⁸⁵

Nonclassical Islet Peptides – Appetite Regulation

The peptide hormones discussed above are considered to be nonclassical islet peptides generated within the pancreas, that mediate numerous local biological actions (Table 1). However, as well as direct pancreatic effects, many of these hormones have well characterised effects outside of the pancreas, that could be linked to pancreatic or extra pancreatic sites of synthesis.

Glucagon-like peptide-1 has a major effect on energy balance and appetite via a complex relationship that is linked to centrally mediated actions.⁸⁶ Physiological effects of GLP-1 include decreased food intake, inhibited gastric emptying and reduced gastric motility.⁸⁷ These effects are facilitated by binding to the GLP-1R and signalling the central nervous system (CNS) via the vagal nervous system.⁸⁸ Glucagon-like peptide-1 is secreted by GCG neurons, which allow direct central activation of the GLP-1R in the NTS of the hypothalamus. GCG neurons signal afferent nerves to relay satiety information to the hypothalamus.⁸⁹ Glucose dependent insulinotropic peptides’ physiological effects on appetite are somewhat disputed, in vitro work using mouse 3T3L1 adipocytes found GIP increases adipogenesis,⁹⁰ whereas chronically reduced GIP in mice attenuates weight gain.⁹¹ However, transgenic overexpression of GIP, as well as GIP agonist treatment in mice reduces obesity related traits.⁹² Moreover, recent clinical studies employing co-activation of GLP-1 and GIP receptors have revealed that GIP can augment the body weight reducing effects of GLP-1.⁹³

As noted above, PYY circulates in distinct bioactive forms, with PYY (3-36) recognised as the foremost circulating PYY peptide postprandially. As well as pancreatic secretion, PYY is released from L-cells of the gut, 15 minutes after food intake, secretion is proportional to calories consumed.⁹⁴ This would indicate that PYY release occurs prior to nutrients reaching the distal small intestine, suggesting secretion is mediated centrally. In addition, there is evidence of enteroendocrine PYY releasing cells in the upper ileum, with studies revealing such cells can express multiple gut hormones,²⁹ which may also be important in this regard.

Rodent receptor KO studies reveal PYY (3-36) acts on the arcuate nucleus (ARC) in the CNS via the NPY2 receptor.⁹⁴ Activation reduces appetite by increasing POMC/α-MSH activity⁹⁵ while suppressing NPY neurons.⁹⁶ Glucagon-like peptide-1 administration is known to cause nausea and gastric complications,⁹⁷ and clinical studies have revealed such side-effects are heightened after PYY(3-36) administration,⁹⁸ indicating related effects on energy regulation. Although CCK increases gallbladder contraction, inhibits gastric emptying and reduces food intake,⁹⁹ many of its effects on energy balance are due to activation of peripheral vagal afferent fibres.¹⁰⁰ However, CCK is also believed to penetrate the blood brain barrier (BBB) to act directly in the CNS to effect appetite and digestion.¹⁰¹

Xenin-25 decreases food intake when administered centrally,¹⁰² or peripherally at elevated doses,¹⁰³ indicating action as a satiety factor. In animal studies, xenin-25 causes anorexia via activation of central NTRS1.¹⁰⁴ This has been supported by work in NTSR1 KO mice, which were nonresponsive to xenin.¹⁰⁵ The mechanisms involved in xenin appetite regulatory effects are poorly described, the extracellular signal-regulated kinases signalling cascade has been implicated, but is not essential for feeding suppression.¹⁰⁵ In addition, a long acting xenin-25 analogue, xenin-25[Lys¹³PAL], lacked effects on energy intake and body weight, but did induce significant benefits on glucose homeostasis in mice.¹⁰⁶

Oxytocin and vasopressin secretion are controlled by signals that regulate appetite,¹⁰⁷ and both hormones are released acutely following a meal.¹⁰⁸ Oxytocin is well established to influence energy balance in vivo, suppressing carbohydrate intake¹⁰⁹ and promoting movement and thermogenesis.¹¹⁰ In rodent brain tissue, OT cells express IRs and glucokinase, and can be activated by insulin and glucose.¹¹¹ Further research identified leptin receptors, as well as receptors allied with other anorectic peptides such as α-MSH, on OT producing cells.¹¹² Ligands of these receptors signal the NTS¹¹³ including noradrenergic A2 cells,¹¹⁴ and these cells directly interact with OT cells.¹¹⁵ Other peptides, such as CCK, may support the energy balance effects of OT at central sites, but further studies are needed to elucidate exact mechanisms.

Therapeutic Potential of Multiagonist Nonclassical Islet Peptides

Dual agonists with nonclassical islet hormone components

Recent novel peptide-based approaches for the treatment of T2D and obesity have focused on simultaneous activation of multiple receptors, many of which are related to nonclassical islet peptide hormones¹¹⁶ (Table 2). Synthetic peptides acting as dual or triagonists at GPCRs have been predicted to have positive effects on energy balance expenditure, glucose homeostasis and appetite.¹¹⁷ Early dual compounds focused on GLP-1/glucagon co-agonism and activity was based on the naturally occurring peptide oxyntomodulin.¹¹⁸ Treatment improved maximum insulin secretion compared with exendin-4¹¹⁹ and resulted in large decreases in food intake, adiposity and increased lipolysis.¹²⁰ Weight loss effects have been linked to significant leptin sensitisation¹²¹ and was successfully translated into phase II clinical trials.¹²² It has been concluded that these peptides have a greater effect than either single hormone. MEDI0382 is a GLP-1/glucagon agonist displaying significant promise in numerous clinical studies, reducing fasting and postprandial glucose and body weight.¹²² MEDI0382 has consistently exhibited a mild adverse event profile.¹²³ Another dual GLP-1/glucagon agonist (SAR425899) also has significant clinical promise, reducing HbA1c and body weight over 28 days, with mild adverse events¹²⁴ (Table 2).

Table 2.

Dual and triagonist peptides with classical/‘nonclassical’ islet peptide components. Table includes peptide hormone components, compound name, main effects and relevant citation(s).

Peptides hormone components	Compound name	Main effects	Reference
Dual agonists
GLP-1/glucagon	MEDI0382	Reduces fasting and postprandial glucose/body weight	^123,124
GLP-1/glucagon	SAR425899	Reduces HbA1c/body weight	¹²⁵
GIP/GLP-1	N-ac (DAla²) GIP/GLP-1-exe	Increases insulin secretion/sensitivity; reduces body weight	¹²⁸
GLP-1/GIP	NNC0090-2746	Reduces HbA1c/body weight	¹¹⁷
GLP-1/GIP	LY3298176	Increases insulin secretion; Reduces HbA1c/body weight	^93,129
GLP-1/xenin	Exendin-4/Xenin-8-Gln	Increases insulin secretion/GIP action, reduces appetite	¹³¹
GLP-1/gastrin	ZP3022	Lowers HbA1c, improves glucose tolerance and β-cell neogenesis	¹³²
GLP-1/PYY	EP45	Lowers blood glucose, stimulates insulin secretion	^133,134
Triagonists
GIP/glucagon/GLP-1	GIP-Oxm	Improves glucose homeostasis, insulin secretion and body weight	¹³⁵
YAG-glucagon	Y¹-dA²-I¹²-N¹⁷-V¹⁸-I²⁷-G^28,29-glucagon	Reduces plasma glucose, food intake and body weight; increases plasma insulin and insulin sensitivity	¹³⁶
GLP-1/GIP/glucagon	HM15211	Improves weight loss, anti-inflammatory and anti-oxidative stress, neuroprotective	^142,143
GLP-1/gastrin/xenin	Exendin-4(Lys²⁷ PAL)/gastrin/xenin-8-Gln	Decreases nonfasting HbA1c, food intake. Enhances insulin levels, glucose tolerance	¹⁴⁴
Glugagon/GLP-1/NPY	GGP817	Unvalidated (FRET analysis)	¹⁴⁵

Abbreviations: FRET, fluorescence resonance energy transfer; GIP, glucose dependent insulinotropic peptide; GLP, glucagon-like peptide; PYY, Peptide Tyrosine Tyrosine.

In recent years, dual incretin agonists have been developed,¹²⁵ these have focused on manipulating GIPR and GLP-1R signalling to reduce food intake and adiposity, and promote combined benefits on pancreatic β-cells.¹²⁶ A novel GIP/GLP-1 agonist (N-ac(DAla2)GIP/GLP-1-exe) activates both incretin receptors to cause concentration dependent insulin secretion from BRIN BD11 β-cells and isolated islets.¹²⁷ Dual receptor activation results in increased weight loss and improved insulin sensitivity compared with mono treatment in mice.¹²⁵ These results have been confirmed in further preclinical work and in clinical studies.¹¹⁶ In a recent Phase 2A clinical trial a GLP-1/GIP dual agonist (NNC0090-2746) with balanced affinity for GLP-1R and GIPR significantly reduced HbA1c and weight over 8 weeks in T2D patients compared with placebo.¹¹⁶ LY3298176 is a fatty acid adapted peptide with GLP-1 and GIP receptor activity, designed to be administered once weekly.¹²⁸ Preclinically, LY3298176 causes glucose-dependent insulin secretion from islets isolated from wild-type, GIPR^−/− and GLP-1R^−/− mice, indicative of activity at both receptors.¹²⁸ LY3298176 has successfully translated preclinical findings into human studies, imparting meaningful enhancement of glycaemic control and body weight⁹³ specifically, reducing Hba1c and body weight greater than a benchmark group taking Dulaglutide. This highlights the importance of balancing receptor interaction when developing dual or triagonists.¹²⁹ It is worth noting that there was a 30% nonresponse rate, but results would indicate that dual incretin agonists are more potent than established mono treatments⁹³ (Table 2).

A novel GLP-1/xenin hybrid also indicated significant therapeutic potential in mice, increasing insulin secretion, reducing appetite and improving GIP action.¹³⁰ A GLP-1/gastrin dual agonist, ZP3022, also displayed multiple antidiabetic effects in vivo. These included lowering HbA1c, improving glucose tolerance and increasing β-cell neogenesis.¹³¹ Dual treatment of GLP-1 and PYY led to a synergistic reduction in food intake.¹³² A recent study characterised a chimeric peptide (EP45) that consists of sequences from exendin-4 (Ex-4) and PYY(3-36), multiple organs can be targeted with this peptide¹³³ (Table 2). Fluorescence resonance energy transfer (FRET) assays demonstrate EP45 stimulates cAMP production via the GLP-1R, while inhibiting cAMP production via the NPY2R.¹³³ These findings would indicate EP45 potentiates blood glucose lowering effects by activating GLP-1R on β-cells, thus triggering glucose stimulated insulin secretion and upregulating insulin gene expression.¹³³ EP45 could also activate receptors centrally to affect appetite and would have relevance for the treatment of T2D.

Triagonists With Nonclassical Islet Hormone Components

The positive results from dual agonist studies have driven the development of triagonists, such as GIP-oxyntomodulin (GIP-Oxm)¹³⁴ and an adapted glucagon peptide (YAG-glucagon).¹³⁵ Most recent work has focused on the incretin/glucagon system and triagonists have been developed to activate the GLP-1/GIP/glucagon receptors.¹³⁶ Glucagon-like peptide-1/glucose dependent insulinotropic peptide and glucagon independently stimulate complementary mechanisms in vivo to cause glucose-mediated insulin secretion,¹³⁷ and reductions in body weight and cholesterol are greater than a dose matched liraglutide treatment.^138,139 In a diabetic rodent model GLP1R-GCGR-GIPR tri-agonism had beneficial pancreatic effects, animals displayed improved glucose tolerance and reduced ab libitum blood glucose, with reduced insulin levels suggesting improved insulin sensitivity¹⁴⁰ (Table 2). Peptide characterisation of triple-acting entities in nonhuman primates has been completed by Sanofi, Novo Nordisk and Hanmi, with Novo Nordisk and Hanmi conducting phase 1 clinical trials.¹²⁹ A long acting GLP-1/GIP/glucagon agonist (HM15211) has a unique pharmacological profile, demonstrating benefits on weight loss and lipid profiles, while exhibiting no risk of hyperglycaemia. Interestingly, in mice HM15211 has also shown promise in treating nonalcoholic steatohepatitis (NASH), fibrosis¹⁴¹ and alzheimers disease¹⁴² (Table 2).

Other triagonists include an enzyme resistant GLP-1/gastrin/xenin peptide which has antidiabetic potential in respect to insulin secretion and enhancement of GIP action,¹⁴³ as well as a triagonist (GGP817) that activates the GluR, GLP-1R and NPY2R.¹⁴⁴ This peptide has not been validated in vivo, but it is thought agonism of GluR would cause increased energy expenditure,¹⁴⁵ GLP-1R activation would result in enhanced β-cell function and improved glucose homeostasis¹⁴⁶ and NPY2R agonism would suppress appetite.⁹⁵

Conclusion

Signalling processes within pancreatic islets are highly complicated,^147,148 and our recent knowledge of an important role for numerous nonclassical islet peptides is these processes requires further detailed study. Understanding their physiology, and potential pathophysiology in diabetes, could open up new promising avenues for drug effective candidates.¹⁹ Both preclinical and clinical evidence demonstrate that metabolic profile can be improved by synergistic action of multiple peptide hormone receptor targets, many of which include nonclassical islet peptides.¹⁴⁹ Such strategies hold great promise for obesity and related forms of diabetes, especially given the optimism generated through early clinical observations.

Footnotes

Funding:

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This review was supported by the EFSD/Lilly European Diabetes Research Programme 2017.

Declaration of Conflicting Interest:

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Author Contributions

AE: Wrote the first draft of the manuscript.

AE,NE: Jointly developed the structure of the paper.

AE, NE: Made critical revisions and appoved final version.

All authers reviewed and approved the final maniscript.

ORCID iD

Andrew English

References

Lopes

Bressan

Peluzio

MDCG

Hermsdorff

HHM

. LINE-1in obesity and cardiometabolic diseases: a systematic review. J Am Coll Nutr. 2019;38:478-484.

Jmel

Romdhane

Ben Halima

, et al. Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations. PLoS ONE. 2018;13:e0194842.

World Health Organisation. Global report on diabetes, 2016. http://www.who.int/diabetes/global-report/en/. Accessed 12 July, 2017.

Baynes

Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab. 2015;6:541.

Longnecker

DS.

Anatomy and Histology of the Pancreas. Pancreapedia: The Exocrine Pancreas Knowledge Base. 2014;4:1-26.

Whitcomb

Lowe

ME.

Human pancreatic digestive enzymes. Dig Dis Sci. 2007;52:1-17.

Meglasson

Matschinsky

FM.

Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabetes Metab Rev. 1986;2:163-214.

Khan

Moffet

Flatt

Kelly

Role of islet peptides in beta cell regulation and type 2 diabetes therapy. Peptides. 2018;100:212-218.

Andralojc

Mercalli

Nowak

, et al. Ghrelin-producing epsilon cells in the developing and adult human pancreas. Diabetologia. 2009;52:486-493.

10.

Tschop

Smiley

Heiman

ML.

Ghrelin induces adiposity in rodents. Nature. 2000;407:908-913.

11.

Unger

Dobbs

Orci

Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu Rev Physiol. 1978;40:307-343.

12.

Samols

Marri

Marks

Interrelationship of glucagon, insulin and glucose. Diabetes. 1966;15:855-866.

13.

Petersen

Vatner

Shulman

GI.

Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol. 2017;13:572-587.

14.

Titchenell

Lazar

Birnbaum

MJ.

Unraveling the regulation of hepatic metabolism by insulin. Trends Endocrinol Metab. 2017;28:497-505.

15.

Seino

Sugawara

Yokoi

Takahashi

β-Cell signalling and insulin secretagogues: a path for improved diabetes therapy. Diabetes Obes Metab. 2017;19:22-29.

16.

Vilsboll

Holst

JJ.

Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 2004;47:357-366.

17.

Tangvarasittichai

Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6:456-480.

18.

Mingrone

Panunzi

De Gaetano

, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964-973.

19.

Brunton

GLP-1 receptor agonists vs. DPP-4 inhibitors for Type 2 Diabetes: is one approach more successful or preferable than the other?

Int J Clin Pract. 2014;68:557-567.

20.

Baggio

Drucker

DJ.

Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-2157.

21.

Kuhre

Gribble

Hartmann

, et al. Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. Am J Physiol Gastrointest Liver Physiol. 2014;306:G622-G630.

22.

Marchetti

Lupi

Bugliani

, et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012;55:3262-3272.

23.

Piro

Mascali

Urbano

, et al. Chronic exposure to GLP-1 increases GLP-1 synthesis and release in a pancreatic alpha cell line (α-TC1): evidence of a direct effect of GLP-1 on pancreatic alpha cells. PLoS ONE. 2014;9:e90093.

24.

De Heer

Rasmussen

Coy

Holst

. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. 2008;51:2263.

25.

Meier

Gallwitz

Siepmann

, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003;46:798-801.

26.

Baggio

Kim

Drucker

DJ.

Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes. 2004;53:S205-S214.

27.

Kazafeos

Incretin effect: GLP-1, GIP, DPP4. Diabetes Res Clin Pract. 2011;93:S32-S36.

28.

Drucker

Erlich

Asa

Brubaker

PL.

Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93:7911-7916.

29.

Egerod

Engelstoft

Grunddal

, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology. 2012;153:5782-5795.

30.

Schmidt

Siegel

Creutzfeldt

Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985;28:704-707.

31.

Holst

JJ.

The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.

32.

Drucker

DJ.

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.

33.

Jorsal

Rhee

Pedersen

, et al. Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. Diabetologia. 2018;61:284-294.

34.

Jackerott

Oster

Larsson

L-I.

PYY in developing murine islet cells: comparisons to development of islet hormones, NPY, and BrdU incorporation. J Histochem Cytochem. 1996;44:809-817.

35.

Bertrand

Gross

Roye

Ahren

Ribes

Evidence for a direct inhibitory effect of PYY on insulin secretion in rats. Pancreas. 1992;7:595-600.

36.

Khan

Vasu

Moffett

Irwin

Flatt

PR.

Islet distribution of peptide YY and its regulatory role in primary mouse islets and immortalised rodent and human beta-cell function and survival. Mol Cell Endocrinol. 2016;436:102-113.

37.

Shi

Loh

Bensellam

, et al. Pancreatic PYY is critical in the control of insulin secretion and glucose homeostasis in female mice. Endocrinology. 2015;156:3122-3136.

38.

Loh

Shi

Y-C

Bensellam

Lee

Laybutt

Herzog

Y1 receptor deficiency in β-cells leads to increased adiposity and impaired glucose metabolism. Scientific Reports. 2018;8:11835.

39.

Portela-Gomes

Johansson

Olding

Grimelius

Co-localization of neuroendocrine hormones in the human fetal pancreas. Eur J Endocrinol. 1999;141:526-533.

40.

Wahlestedt

Regunathan

Reis

DJ.

Identification of cultured cells selectively expressing Y1-, Y2-, or Y3-type receptors for neuropeptide Y/peptide YY. Life Sci. 1992;50:PL7-PL12.

41.

Whim

MD.

Pancreatic beta cells synthesize neuropeptide Y and can rapidly release peptide co-transmitters. PLoS ONE. 2011;6:e19478.

42.

Bado

Cloarec

Moizo

Laigneau

J-P

Bataille

Lewin

Neurotensin and oxyntomodulin-(30-37) potentiate PYY regulation of gastric acid and somatostatin secretions. Am J Physiol. 1993;265:G113-G117.

43.

Ramracheya

McCulloch

Clark

, et al. PYY-dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following Roux-En-Y gastric bypass surgery. Cell Rep. 2016;15:944-950.

44.

Khan

Vasu

Moffett

Irwin

Flatt

PR.

Influence of neuropeptide Y and pancreatic polypeptide on islet function and beta-cell survival. Biochim Biophys Acta Gen Subj. 2017;1861:749-758.

45.

Myrsen-Axcrona

Karlsson

Sundler

Ahren

Dexamethasone induces neuropeptide Y (NPY) expression and impairs insulin release in the insulin-producing cell line RINm5F. J Biol Chem. 1997;272:10790-10796.

46.

Innis

Snyder

SH.

Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A. 1980;77:6917-6921.

47.

Rehfeld

JF.

CCK, gastrin and diabetes mellitus. Biomark Med. 2016;10:1125-1127.

48.

Rehfeld

JF.

Why cholecystokinin and gastrin are also incretins. Cardiovasc Endocrinol Metab. 2016;5:99-101.

49.

Rehfeld

Holst

Kuhl

The effect of gastrin on basal and aminoacid-stimulated insulin and glucagon secretion in man. Eur J Clin Invest. 1978;8:5-9.

50.

Hansky

Soveny

Korman

The effect of glucagon on serum gastrin: I Studies in normal subjects. Gut. 1973;14:457-461.

51.

Boushey

Abadir

Flamez

, et al. Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. Gastroenterology. 2003;125:1164-1174.

52.

Rooman

Bouwens

Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia. 2004;47:259-265.

53.

Ahren

Holst

Efendic

Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J Clin Endocrinol Metab. 2000;85:1043-1048.

54.

Linnemann

Davis

DB.

Glucagon-like peptide-1 and cholecystokinin production and signaling in the pancreatic islet as an adaptive response to obesity. J Diabetes Investig. 2016;7:44-49.

55.

Hunter

Carpenter

Swiger

, et al. Discovery of novel, potent and long acting CCK analogs. Paper presented 24th American Peptide Symposium (eds Srivastava

Yudin

Lebl

). American Peptide Society; 2015. https://pdfs.semanticscholar.org/10fc/54dab5a30e230672c6026bd1243becff9323.pdf.

56.

Klement

Hunyadi-Gulyás

Medzihradszky

. Biological significance and analysis of tyrosine sulfation. In: Griffiths

Unwin

, eds. Analysis of Protein Post-Translational Modifications by Mass Spectrometry. Hoboken, NJ: John Wiley & Sons; 2016:333-349.

57.

Linnemann

Neuman

Battiola

Wisinski

Kimple

Davis

DB.

Glucagon-like peptide-1 regulates cholecystokinin production in β-cells to protect from apoptosis. Mol Endocrinol. 2015;29:978-987.

58.

Williams

JA.

Cholecystokinin (CCK) regulation of pancreatic acinar cells: physiological actions and signal transduction mechanisms. Compr Physiol. 2019;9:535-564.

59.

Lippo

Batista

de Rezende

, et al. Low-protein diet disrupts the crosstalk between the PKA and PKC signaling pathways in isolated pancreatic islets. J Nutr Biochem. 2015;26:556-562.

60.

Chen

Vaughan

Lee

Vale

Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. Proc Natl Acad Sci U S A. 2007;104:4206-4211.

61.

Chen

Vaughan

, et al. Urocortin III is expressed in pancreatic β-cells and stimulates insulin and glucagon secretion. Endocrinology. 2003;144:3216-3224.

62.

van der Meulen

Donaldson

Caceres

, et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat Med. 2015;21:769.

63.

Portela-Gomes

Stridsberg

Grimelius

Oberg

Janson

ET.

Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126-132.

64.

Strowski

Parmar

Blake

Schaeffer

JM.

Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000;141:111-117.

65.

Neelankal John

Ram

Jiang

. RNA-seq analysis of islets to characterise the dedifferentiation in type 2 diabetes model mice db/db. Endocr Pathol. 2018;29:207-221.

66.

Stridsberg

Sandler

Wilander

Cosecretion of islet amylid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of β-cell function. Regulatory Peptides. 1993;45:363-370.

67.

Hay

Christopoulos

Sexton

Amylin receptors: molecular composition and pharmacology. Biochem Soc Trans. 2004;32:865-867.

68.

Grizzanti

Corrigan

Servizi

Casadesus

Amylin signaling in diabetes and Alzheimer’s disease: therapy or pathology?

J Neurol Neuromedicine 2019;4:12-16.

69.

Riddle

Nahra

Han

, et al. Control of postprandial hyperglycemia in type 1 diabetes by 24-hour fixed-dose coadministration of pramlintide and regular human insulin: a randomized, two-way crossover study. Diabetes Care. 2018;41:2346-2352.

70.

Kiriyama

Nochi

Role and cytotoxicity of amylin and protection of pancreatic islet β-cells from amylin cytotoxicity. Cells. 2018;7:95.

71.

Martin

Parthsarathy

Pathak

Gault

Flatt

Irwin

Characterisation of the biological activity of xenin-25 degradation fragment peptides. J Endocrinol. 2014;221:193-200.

72.

Khan

Vasu

Moffett

Gault

Flatt

Irwin

Locally produced xenin and the neurotensinergic system in pancreatic islet function and β-cell survival. Biological Chemistry. 2017;399:79-92.

73.

Wice

Wang

Crimmins

, et al. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. J Biol Chem. 2010;285:19842-19853.

74.

Wang

Oestricker

Wallendorf

, et al. Cholinergic signaling mediates the effects of xenin-25 on secretion of pancreatic polypeptide but not insulin or glucagon in humans with impaired glucose tolerance. PLoS ONE. 2018;13:e0192441.

75.

Molina

Rodriguez-Diaz

Fachado

Jacques-Silva

Berggren

P-O

Caicedo

Control of insulin secretion by cholinergic signaling in the human pancreatic islet. Diabetes. 2014;63:2714-2726.

76.

Baribeau

Anagnostou

Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015;9:335.

77.

Mohan

Moffett

Thomas

Irwin

Flatt

PR.

Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival. Biochimie. 2019;158:191-198.

78.

Mohan

Khan

Moffett

Irwin

Flatt

PR.

Oxytocin is present in islets and plays a role in beta-cell function and survival. Peptides. 2018;100:260-268.

79.

Carter

CS.

The oxytocin-vasopressin pathway in the context of love and fear. Front Endocrinol. 2017;8:356.

80.

Elabd

Sabry

Two birds with one stone: possible dual-role of oxytocin in the treatment of diabetes and osteoporosis. Front Endocrinol. 2015;6:121.

81.

Nishitani

Rindi

Lopez

Upchurch

Leiter

Transcriptional regulation of secretin gene expression. J Clin Gastroenterol. 1995;21:S50-S55.

82.

DiGregorio

Sharma

Physiology, Secretin. Treasure Island, FL: Statpearls Publishing; 2018.

83.

Kraegen

Chisholm

Young

Lazarus

. The gastrointestinal stimulus to insulin release. II. A dual action of secretin. J Clin Invest. 1970;49:524-529.

84.

Santeusanio

Faloona

Unger

RH.

Suppressive effect of secretin upon pancreatic alpha cell function. J Clin Invest. 1972;51:1743-1749.

85.

Chey

Lee

Chang

Chen

Y-F

Millikan

Potentiating effect of secretin on cholecystokinin-stimulated pancreatic secretion in dogs. Am J Physiol. 1984;246:G248-G252.

86.

Krieger

J-P

Santos

Conceicao

Sanchez-Watts

, et al. Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats. Am J Physiol Regul Integr Comp Physiol. 2018;315:R708-R720.

87.

Aaboe

Krarup

Madsbad

Holst

JJ.

GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab. 2008;10:994-1003.

88.

Krieger

J-P

Arnold

Pettersen

Lossel

Langhans

Lee

SJ.

Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes. 2016;65:34-43.

89.

Lefort

Tschop

Garcia-Caceres

A synaptic basis for GLP-1 action in the brain. Neuron. 2017;96:713-715.

90.

Getty-Kaushik

Song

Boylan

Corkey

Wolfe

MM.

Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity. 2006;14:1124-1131.

91.

Nasteska

Harada

Suzuki

, et al. Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes. 2014;63:2332-2343.

92.

Irwin

McClean

O’harte

Gault

Harriott

Flatt

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro 3) GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia. 2007;50:1532-1540.

93.

Frias

Nauck

Van

, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180-2193.

94.

Blevins

Chelikani

Haver

Reidelberger

PYY (3-36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats. Peptides. 2008;29:112-119.

95.

De Silva

Bloom

. Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver. 2012;6:10-20.

96.

Jones

Nunn

Chambers

Ostergaard

Wulff

Luckman

SM.

Modified peptide YY molecule attenuates the activity of NPY/AgRP neurons and reduces food intake in male mice. Endocrinology. 2019;160:2737-2747.

97.

Astrup

Carraro

Finer

, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843-854.

98.

Degen

Oesch

Casanova

, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology. 2005;129:1430-1436.

99.

Muurahainen

Kissileff

Derogatis

Pi-Sunyer

FX.

Effects of cholecystokinin-octapeptide (CCK-8) on food intake and gastric emptying in man. Physiol Behav. 1988;44:645-649.

100.

Schwartz

GJ.

Roles for gut vagal sensory signals in determining energy availability and energy expenditure. Brain Res. 2018;1693:151-153.

101.

Austin

Marks

Hormonal regulators of appetite. Int J Pediat Endocrin. 2008;2009:141753.

102.

Craig

Gault

Irwin

Emerging therapeutic potential for xenin and related peptides in obesity and diabetes. Diabetes Metab Res Rev. 2018;34:e3006.

103.

Taylor

Irwin

McKillop

Patterson

Flatt

Gault

VA.

Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. J Endocrinol. 2010;207:87-93.

104.

Bhavya

Lew

Mizuno

TM.

Central action of xenin affects the expression of lipid metabolism-related genes and proteins in mouse white adipose tissue. Neuropeptides. 2017;63:67-73.

105.

Kim

San Lew

Spirkina

Mizuno

TM.

Xenin-induced feeding suppression is not mediated through the activation of central extracellular signal-regulated kinase signaling in mice. Behav Brain Res. 2016;312:118-126.

106.

Gault

Martin

Flatt

Parthsarathy

Irwin

Xenin-25 [Lys 13 PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential. Acta Diabetologica. 2015;52:461-471.

107.

Freeman

Ngo

Singh

Masnaghetti

Bales

Blevins

JE.

Effects of chronic oxytocin administration and diet composition on oxytocin and vasopressin 1a receptor binding in the rat brain. Neuroscience. 2018;392:241-251.

108.

Ong

Alhadeff

Grill

HJ.

Medial nucleus tractus solitarius oxytocin receptor signaling and food intake control: the role of gastrointestinal satiation signal processing. Am J Physiol Regul Integr Comp Physiol. 2015;308:R800-R806.

109.

Klockars

Levine

Olszewski

PK.

Central oxytocin and food intake: focus on macronutrient-driven reward. Front Endocrinol. 2015;6:65.

110.

Lawson

Marengi

DeSanti

Holmes

Schoenfeld

Tolley

CJ.

Oxytocin reduces caloric intake in men. Obesity. 2015;23:950-956.

111.

Zhang

Nakata

Nakae

Ogawa

Yada

Central insulin action induces activation of paraventricular oxytocin neurons to release oxytocin into circulation. Sci Rep. 2018;8:10415.

112.

Engineer

Garcia

JM.

Leptin in anorexia and cachexia syndrome. Int J Pept. 2012;2012:287457.

113.

Bassi

Furuya

Zoccal

, et al. Control of respiratory and cardiovascular functions by leptin. Life Sci. 2015;125:25-31.

114.

Rinaman

Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cognitive, and behavioral functions. Am J Physiol Regul Integr Comp Physiol. 2010;300:R222-R235.

115.

Zhu

Onaka

Involvement of medullary A2 noradrenergic neurons in the activation of oxytocin neurons after conditioned fear stimuli. Eur J Neurosci. 2002;16:2186-2198.

116.

Frias

Bastyr

3rd Vignati

, et al. The sustained effects of a dual GIP/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metab. 2017;26:343-352.e2.

117.

Moran

McKillop

O’Harte

. Development of novel ligands for peptide GPCRs. Curr Opin Pharmacol. 2016;31:57-62.

118.

Pocai

Carrington

Adams

, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58:2258-2266.

119.

Farooq

Jones

Minnion

Bloom

SR.

Effect of biased GLP-1/Glucagon receptor co-agonists on insulin secretion. Diabetes. 2018;67:1100.

120.

Day

Gelfanov

Smiley

, et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers. 2012;98:443-450.

121.

Patel

Joharapurkar

Dhanesha

, et al. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. Can J Physiol Pharmacol. 2013;91:1009-1015.

122.

Ambery

Parker

Stumvoll

, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391:2607-2618.

123.

Ambery

Klammt

Posch

, et al. MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study. Br J Clin Pharmacol. 2018;84:2325-2335.

124.

Tillner

Posch

Wagner

, et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab. 2019;21:120-128.

125.

Finan

Ottaway

, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013;5:209ra151.

126.

Skow

Bergmann

Knop

FK.

Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’. Diabetes Obes Metab. 2016;18:847-854.

127.

Pathak

Gault

McClean

Irwin

Flatt

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential. Biochem Pharmacol. 2018;155:264-274.

128.

Coskun

Sloop

Loghin

, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14.

129.

Brandt

Muller

DiMarchi

Tschop

Stemmer

Peptide-based multi-agonists: a new paradigm in metabolic pharmacology. J Intern Med. 2018;284:581-602.

130.

Hasib

Khan

Gault

Flatt

Irwin

A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice. Peptides. 2018;100:202-211.

131.

Skarbaliene

Rigbolt

Fosgerau

Billestrup

In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes. Eur J Pharmacol. 2017;815:181-189.

132.

Neary

Small

Druce

, et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology. 2005;146:5120-5127.

133.

Chepurny

Bonaccorso

Leech

, et al. Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors. Scientific Reports. 2018;8:3749.

134.

Bhat

Kerr

Flatt

Gault

VA.

A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties. Biochem Pharmacol. 2013;85:1655-1662.

135.

Bhat

Kerr

Vasu

Flatt

Gault

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice. Diabetologia. 2013;56:1417-1424.

136.

Jall

Sachs

Clemmensen

, et al. Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol Metab. 2017;6:440-446.

137.

Nauck

Bartels

Orskov

Ebert

Creutzfeldt

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76:912-917.

138.

Gault

Bhat

Irwin

Flatt

PR.

A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. J Biol Chem. 2013;288:35581-35591.

139.

Brandt

Gotz

Tschop

Muller

TD.

Gut hormone polyagonists for the treatment of type 2 diabetes. Peptides. 2018;100:190-201.

140.

Kaur

Allahbadia

Singh

Are we at the verge of finding a new efficacious pharmacotherapy for obesity in the form of agonism at triple drug receptors: glucagon, Glucagon like peptide1 (GLP1), glucose dependent insulin tropic peptide (GIP). Int Phys Med Rehab J. 2019;3:22-27.

141.

Choi

Kim

Lee

, et al. Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model. Diabetes. 2018;67:1106.

142.

Camins

Ettcheto

Busquets

, et al. Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease. Expert Opin Investig Drugs. 2019;28:93-97.

143.

Hasib

Khan

Gault

Flatt

Irwin

Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln. Eur J Pharmacol. 2018;834:126-135.

144.

Chepurny

Matsoukas

M-T

Liapakis

, et al. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. J Biol Chem. 2019;294:3514-3531.

145.

Szalowska

te Meerman

Hoek

Vonk

RJ.

Adipokines and energy metabolism genes, but not proinflammatory genes are deregulated in patients with higher HOMA and lower HDL. In: Ewa

, ed. An Adipocentric View of the Development of Insulin Resistance. 2011:107. https://www.rug.nl/research/portal/files/2490617/thesis_ewa_new2.pdf.

146.

Shin

Le Lay

Everett

Gupta

Rafiq

Kaestner

KH.

CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse β-cells. Mol Metab. 2014;3:803-812.

147.

Barker

Leibiger

Berggren

P-O.

The pancreatic islet as a signaling hub. Adv Biol Regul. 2013;53:156-163.

148.

Aamodt

Powers

AC.

Signals in the pancreatic islet microenvironment influence β-cell proliferation. Diabetes Obes Metab. 2017;19:124-136.

149.

Finan

Yang

Ottaway

, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21:27-36.

Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions

Abstract

Keywords

Introduction

Classical Islet Peptides

Nonclassical Islet Peptides – Pancreatic Effects

Incretin and related peptides

Peptide Tyrosine Tyrosine

Gastrin and cholecystokinin

Urocortin3 and islet amyloid polypeptide

Xenin-25 and neurotensin

Vasopressin, oxytocin, and secretin

Nonclassical Islet Peptides – Appetite Regulation

Therapeutic Potential of Multiagonist Nonclassical Islet Peptides

Dual agonists with nonclassical islet hormone components

Triagonists With Nonclassical Islet Hormone Components

Conclusion

Footnotes

Funding:

Declaration of Conflicting Interest:

Author Contributions

ORCID iD

References